GIA632

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for GIA632, covering 2026-04-06 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo [Phase 2]

See pricing